Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Indaptus Therapeutics, Inc. Common Stock

INDP

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Last trade $3.28
Day change -$0.175 (-5.07%)
Day range $3.14 – $3.58
Volume 224,008
Market cap $530M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$529.93M
Price / earnings
—
Price / book
46.6×
Price / sales
—
EV / sales
—
EV / EBITDA
-35.36×

Profitability

Earnings per share
-$0.10
Return on assets
-128.66%
Return on equity
-135.62%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
19.48×
Quick ratio
19.48×
Cash ratio
12.27×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$14.7M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for INDP, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.45M$1.67M$5.31M$1.13M$2.29M$1.76M$1.69M$1.68M
Research and development$363.13K$491.13K$2.85M$1.52M$2.17M$2.81M$2.48M$1.47M
Total operating expenses$1.81M$2.16M$8.16M$2.65M$4.46M$4.57M$4.17M$3.14M
Operating income-$1.81M-$2.16M-$8.16M-$2.65M-$4.46M-$4.57M-$4.17M-$3.14M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$1.79M-$2.54M-$8.11M-$2.98M-$5.23M-$4.53M-$4.13M-$3.07M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.79M-$2.54M-$8.11M-$2.98M-$5.23M-$4.53M-$4.13M-$3.07M
Net income attributable to common shareholders-$1.79M-$2.54M-$8.11M-$2.98M-$5.23M-$4.53M-$4.13M-$3.07M
EBITDA-$1.81M-$2.16M-$8.16M-$2.65M-$4.46M-$4.57M-$4.17M-$3.14M
Basic earnings per share-$0.02-$0.23-$4.52-$2.98-$9.09-$9.11-$10.59-$9.04
Diluted earnings per share-$0.02-$0.23-$4.52-$2.98-$9.09-$9.11-$10.59-$9.04

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics, a clinical-stage biotechnology company, highlights its accomplishments in 2024 and outlines its strategic goals for 2025, including the launch of a combination trial with BeiGene's tislelizumab and the expansion of its Decoy20 clinical trial.

GlobeNewswire Inc.

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 27, 20251-for-28reverse split
Jul 27, 20211-for-4reverse split
Oct 30, 20201-for-20reverse split